Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wilkerson

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
The Journal of Biological Chemistry|January 4, 2020
Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cellsIan M McDonald, Gavin D Grant, Michael P East, et al.
The Journal of Pathology|January 19, 2012
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selectionLucia Hernandez, Paul M Wilkerson, Maryou B Lambros, et al.
Cancer Discovery|December 8, 2019
TBK1 Is a Synthetic Lethal Target in Cancer with <i>VHL</i> LossLianxin Hu, Haibiao Xie, Xijuan Liu, et al.
Molecular Oncology|July 22, 2014
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breastSalvatore Piscuoglio, Charlotte K Y Ng, Luciano G Martelotto, et al.
Journal of Managed Care & Specialty Pharmacy|March 26, 2016
Impact of Clinical Pharmacy Specialists on the Design and Implementation of a Quality Improvement Initiative to Decrease Inappropriate Medications in a Veterans Affairs Emergency DepartmentJason M Moss, William E Bryan, Loren M Wilkerson, et al.
The Journal of Pathology|October 26, 2011
Immunophenotypic and genomic characterization of papillary carcinomas of the breastRaphaëlle Duprez, Paul M Wilkerson, Magali Lacroix-Triki, et al.
Breast Cancer Research : BCR|April 19, 2015
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancerElena López-Knowles, Paul M Wilkerson, Ricardo Ribas, et al.
Breast Cancer Research : BCR|March 22, 2012
Functional characterization of the 19q12 amplicon in grade III breast cancersRachael Natrajan, Alan Mackay, Paul M Wilkerson, et al.
Journal of Pharmacy Practice|December 27, 2017
An Interdisciplinary Academic Detailing Approach to Decrease Inappropriate Medication Prescribing by Physician Residents for Older Veterans Treated in the Emergency DepartmentJason M Moss, William E Bryan, Loren M Wilkerson, et al.
Histopathology|February 13, 2013
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutationsDaniel Wetterskog, Paul M Wilkerson, Daniel N Rodrigues, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Biological Chemistry|January 4, 2020
Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cellsIan M McDonald, Gavin D Grant, Michael P East, et al.
The Journal of Pathology|January 19, 2012
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selectionLucia Hernandez, Paul M Wilkerson, Maryou B Lambros, et al.
Cancer Discovery|December 8, 2019
TBK1 Is a Synthetic Lethal Target in Cancer with <i>VHL</i> LossLianxin Hu, Haibiao Xie, Xijuan Liu, et al.
Molecular Oncology|July 22, 2014
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breastSalvatore Piscuoglio, Charlotte K Y Ng, Luciano G Martelotto, et al.
Journal of Managed Care & Specialty Pharmacy|March 26, 2016
Impact of Clinical Pharmacy Specialists on the Design and Implementation of a Quality Improvement Initiative to Decrease Inappropriate Medications in a Veterans Affairs Emergency DepartmentJason M Moss, William E Bryan, Loren M Wilkerson, et al.
The Journal of Pathology|October 26, 2011
Immunophenotypic and genomic characterization of papillary carcinomas of the breastRaphaëlle Duprez, Paul M Wilkerson, Magali Lacroix-Triki, et al.
Breast Cancer Research : BCR|April 19, 2015
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancerElena López-Knowles, Paul M Wilkerson, Ricardo Ribas, et al.
Breast Cancer Research : BCR|March 22, 2012
Functional characterization of the 19q12 amplicon in grade III breast cancersRachael Natrajan, Alan Mackay, Paul M Wilkerson, et al.
Journal of Pharmacy Practice|December 27, 2017
An Interdisciplinary Academic Detailing Approach to Decrease Inappropriate Medication Prescribing by Physician Residents for Older Veterans Treated in the Emergency DepartmentJason M Moss, William E Bryan, Loren M Wilkerson, et al.
Histopathology|February 13, 2013
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutationsDaniel Wetterskog, Paul M Wilkerson, Daniel N Rodrigues, et al.
Pageof 9